# Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

> **NCT01605162** · PHASE2 · TERMINATED · sponsor: **Eisai Inc.** · enrollment: 8 (actual)

## Conditions studied

- Wild Type BRAF Stage IV Melanoma
- Unresectable Stage III Melanoma

## Interventions

- **DRUG:** TMZ
- **DRUG:** E7016

## Key facts

- **NCT ID:** NCT01605162
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2016-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01605162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01605162, "Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01605162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*